Please login to the form below

Not currently logged in
Email:
Password:

ITP

This page shows the latest ITP news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs. Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... ITP is a disease caused by low platelet counts that lead to bruising, bleeding and fatigue.

Latest news

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... ITP is an autoimmune disease where

  • CHMP backs orphan drugs Uptravi and Coagadex CHMP backs orphan drugs Uptravi and Coagadex

    new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    Revolade - sold as Promacta in the US - has previously been approved to treat the rare disorder chronic immune thrombocytopenia (ITP) in Europe and is also authorised for both ITP and SAA ... Epstein said recent approvals in SAA and paediatric ITP will

  • Novartis gets FDA nod for rare blood disorder drug Novartis gets FDA nod for rare blood disorder drug

    The FDA has approved Novartis' Promacta for the treatment of children over six with chronic immune thrombocytopenia (ITP), seven years after it was given the nod for adults. ... patients taking concomitant ITP medications were also able to reduce of

  • Baxalta will add $2.5bn in new product turnover by 2020 Baxalta will add $2.5bn in new product turnover by 2020

    In March Baxter also cut a $225m deal to buy SuppreMol - adding a lead product for treatment of ITP and lupus in phase II trials to Baxalta's portfolio - while last

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics